Search hospitals > Ohio > Newark
Newark Radiation Oncology
Claim this profileNewark, Ohio 43055
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
165 reported clinical trials
2 medical researchers
Summary
Newark Radiation Oncology is a medical facility located in Newark, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Newark Radiation Oncology is involved with conducting 165 clinical trials across 352 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
John P. KueblerStrecker Cancer Center-Belpre12 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Carcinoma
1 reported clinical trial
5 drugs studied
Clinical Trials running at Newark Radiation Oncology
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Melanoma
Cutaneous Melanoma
Cancer
Bladder Cancer
Multiple Myeloma
Renal Cell Carcinoma
Cognitive Training
for Breast Cancer Survivors
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Recruiting1 award N/A5 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Newark Radiation Oncology?
Newark Radiation Oncology is a medical facility located in Newark, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Newark Radiation Oncology is involved with conducting 165 clinical trials across 352 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.